Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,607.98 91.71 0.63%
TOPIX 1,178.17 4.80 0.41%
HANG SENG 22,760.24 64.23 0.28%

Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS)



  Illumina Technology Enables Findings of the Collaborative Oncological
  Gene-Environment Study (COGS)

 Custom iSelect® Genotyping Array Designed in Collaboration with Consortia to
        Advance Understanding of Cancer; Study Results Published Today

Business Wire

SAN DIEGO -- March 27, 2013

Illumina, Inc. (NASDAQ: ILMN) announced that its iCOGS custom array was used
to identify genetic variants related to breast, ovary and prostate cancer as
part of the Collaborative Oncological Gene-Environment Study (COGS), the
results of which were published today in Nature Genetics and other leading
journals.^1 Developed in collaboration with four large consortia^2 involved in
the study, the iCOGS array enables significant advances in understanding the
genetic basis of cancer.

Specifically, the iCOGS array identifies single-nucleotide polymorphisms
(SNPs) across selected regions of DNA associated with cancer. Its 200,000 SNPs
were drawn from previous genome-wide association studies of the different
cancer types and subtypes; associations with disease survival or other traits
that are associated with risk of cancer; and functional candidates. The
technology was used to test more than 200,000 individuals participating in the
COGS.

“This groundbreaking study demonstrates how genomic technology is advancing
cancer research,” said Jay Flatley, Illumina’s President and Chief Executive
Officer. “We applaud the efforts of the consortia, and are pleased the iCOGS
array played a role in enabling this research that ultimately will help
patients.”

The COGS findings include a striking increase in the number of genetic
associations for breast, ovarian and prostate cancer – nearly doubling the
number of known susceptibility regions. The findings also provide insights
into the differences between subtypes of cancer, including those revealed from
comparisons of Estrogen Receptor+ and Estrogen Receptor- breast cancers, as
well as the pathways and mechanisms involved in susceptibility to these common
cancers.

David Bentley, Vice President and Chief Scientist at Illumina added, “The
partnership of the consortia and their work with us unified an enormous depth
of knowledge to create a single, specialized array for application to the
entire study cohort. Ultimately, we believe the results of the COGS have
significant implications in the understanding and management of cancer.”

To read the papers, visit: http://www.nature.com/icogs/.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

^1 Human Molecular Genetics, Nature Communications, PLoS Genetics, and The
American Journal of Human Genetics.

^2 The Breast Cancer Association Consortium (BCAC), the Ovarian Cancer
Association Consortium (OCAC), the Prostate Cancer Association Group to
Investigate Cancer Associated Alterations in the Genome (PRACTICAL), and the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement